Clinical trials: Induction Chemotherapy
Neoplasms, Heart Failure
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
Anthracyclines are associated with cardiotoxic effects. Previous studies suggest that enalapril, and or carvedilol, protect against cardiovascular effects of these drugs.
- Conditions
- Neoplasms, Heart Failure, Cardiotoxicity, Chemotherapy Effect
- Trial name
- IPAC (NCT03650205)
- Testing
- Ivabradine
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- University of Sao Paulo
Breast Cancer, Breast Neoplasms
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple…
- Trial name
- NCT04373031
- Testing
- Pembrolizumab, IRX 2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Providence Health & Services
Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT05979961
- Testing
- IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- 8 sites in China
- Volunteers
- 464 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Malignant Neoplasm, Oral Cancer
Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Epidermal growth factor receptor（EGFR） is a potential target for new anticancer therapy in head and neck squamous cell carcinoma, because blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the…
- Conditions
- Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma
- Trial name
- NCT01440270
- Testing
- Neo-adjuvant Erbitux-based chemotherapy
- Where
- 7 sites in China
- Volunteers
- 145 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chemotherapy-induced Peripheral Neuropathy
Wearable Focal Vibration for Chemotherapy-Induced Peripheral Neuropathy
This study will perform an early Phase I feasibility study with single-arm, double-baseline repeated measured design. The investigators will test the feasibility of using focal vibration to improve symptoms of persistent CIPN.
- Trial name
- NCT04959929
- Testing
- Focal vibration therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Oklahoma
Septic Shock, Nonchemotherapy Drug-induced Neutropenia
Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Septic shock remains a significant clinical problem associated with high rates of mortality among neutropenic patient despite antimicrobial therapy and supportive care.
- Conditions
- Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients, Neutropenia in Patients With Aplastic Anemia
- Trial name
- NCT01849237
- Testing
- Mesenchymal stromal cells, Standard therapy of septic shock
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation…
- Conditions
- Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00895245
- Testing
- fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)
This is a multicenter, randomized, open-label, paralleled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) efficacy compared with the ondansetron…
- Trial name
- NCT01659775
- Testing
- Sancuso patch, Zofran inj.+Zofran tab.
- Where
- South Korea
- Volunteers
- 389 people
- Sponsor
- LG Life Sciences
Neuroblastoma, Pediatric Cancer
A Study of N9 Chemotherapy in Children With Neuroblastoma
The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times …
- Trial name
- NCT04947501
- Testing
- Cyclophosphamide, Topotecan, Vincristine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer Metastatic, First-line Treatment
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer
This prospective, multi-center, open-label, phase II, randomized controlled trial (CCICC-002b) is to evaluate the efficacy and safety of autologous cytokine-induced killer cell immunotherapy in combination with PD-1 inhibitor and…
- Trial name
- CCICC-002b (NCT04836728)
- Testing
- CIK cells injection, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Peripheral Neuropathy
Central Mechanisms of Calmare: an fMRI Trial
Pilot one-treatment and extended 10-treatment studies are carried out on participants with peripheral neuropathy comparing traditional TENS and Calmare stimulation protocols using a double-blind apparatus.
- Trial name
- NCT04242797
- Testing
- Calmare, TENS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Brigham Young University
NSCLC (Advanced Non-small Cell Lung Cancer)
FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer
Moving immunotherapy ahead of chemoradiotherapy in a "sandwich" model-where tumor reduction is achieved through induction chemo-immunotherapy, immunotherapy is paused during chemoradiotherapy, and then resumed as maintenance…
- Trial name
- NCT07418866
- Testing
- Paclitaxel Micelles ; Cisplatin ; 5-FU ; Serplulimab, High-Low Mixed-Dose Radiotherapy Group
- Volunteers
- 70 people
- Sponsor
- Fudan University
Cardiomyopathy Due to Anthracyclines
Stem Cell Injection in Cancer Survivors
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction…
- Trial name
- SENECA (NCT02509156)
- Testing
- Allo-MSCs
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cardiotoxicity, Breast Cancer
Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based chemotherapy.
- Trial name
- PROTECT-COR (NCT06622954)
- Testing
- Protein- and Calorie restriction
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting
Community-Led Action Research in Oncology: Improving Symptom Management
This study will be conducted at La Liga Contra el Cancer in San Pedro Sula, Honduras. The overall objective of this project is to improve symptom management for patients undergoing chemotherapy in Honduras.
- Conditions
- Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression
- Trial name
- CLARO (NCT03208816)
- Testing
- symptom management program for chemotherapy patients
- Where
- 2 sites in United States, Honduras
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Head and Neck Cancer
Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer
More than 50% of Head and Neck cancers are locally advanced at presentation. Although surgery, in combination with other modalities like radiation therapy can achieve 40-50% five year survival rates, resection in the head and…
- Trial name
- DREXNECK (NCT01467115)
- Testing
- Radiotherapy, Leucovorin, Cetuximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Drexel University College of Medicine
Head and Neck Cancer, Squamous Cell Cancer
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
This study seeks to develop a new induction chemotherapy regimen which is a combination of two pill drugs taken by mouth and two drugs given by vein.
- Trial name
- NCT01721525
- Testing
- Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Ovarian Neoplasm
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
Paclitaxel, a widely used chemotherapeutic agent, is associated with several well-known side effects including neuropathy (weakness, numbness and pain) and generalized body aches.
- Conditions
- Breast Cancer, Ovarian Neoplasm, Pain
- Trial name
- NCT01821833
- Testing
- Omega-3 fatty acid, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- New Mexico Cancer Research Alliance
Chemotherapy, Radiation Therapy
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
The investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy of potentially resectable advanced…
- Trial name
- NCT05821452
- Testing
- Camrelizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Medical University Union Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.